How do you feel about the article, “Anti-smoking vaccine could soon be available”?
* Science News * Space * Dinosaurs * Evolution * View from the Lab * Science Picture Galleries 1. Home 2. Science Anti-smoking vaccine could soon be available Smokers could soon have access to an injectable vaccine to help them break the habit following a deal between the company that developed the drug and manufacturer Glaxosmithkline. By Martin Evans Published: 1:22PM BST 10 Aug 2009 Anti-smoking vaccine could soon be available The vaccine is injected and works by creating anti-bodies that bind to nicotine molecules, preventing them from passing the blood into the brain Photo: NicVAX The NicVAX vaccine works by preventing nicotine in tobacco entering the brain, where it creates an addictive sensation of pleasure. Trials have shown it can halve the number of people who return to smoking after trying to give up. While a large number of products are currently available success rates for permanently giving up tobacco are varied. Figures from the American Lung Association suggest that rel
The NicVAX vaccine works by preventing nicotine in tobacco entering the brain, where it creates an addictive sensation of pleasure. Trials have shown it can halve the number of people who return to smoking after trying to give up. While a large number of products are currently available success rates for permanently giving up tobacco are varied. Figures from the American Lung Association suggest that relapse rates among smokers are as high as 90 per cent within a year of quitting. But the vaccine, which is injected, works by creating anti-bodies that bind to nicotine molecules, preventing them from passing the blood into the brain. If successful the vaccine could help prevent millions of smoking related deaths around the world. GSK will pay £24 million up front and as much as £296 million to the drug’s developer Nabi as part of the deal which will give the company a leading edge in the lucrative smoking cessation market. Jean Stephenne, president of GSK’s Biologicals division said: “If
The NicVAX vaccine works by preventing nicotine in tobacco entering the brain, where it creates an addictive sensation of pleasure. Trials have shown it can halve the number of people who return to smoking after trying to give up. GSK will pay £24 million up front and as much as £296 million to Nabi as part of the deal which will give the company a leading edge in the lucrative smoking cessation market. While a large number of products are currently available success rates for permanently giving up tobacco are varied. Figures from the American Lung Association suggest that relapse rates among smokers are as high as 90 per cent within a year of quitting. But the vaccine, which is injected, works by creating anti-bodies that bind to nicotine molecules, preventing them from passing the blood into the brain. If successful the vaccine could help prevent millions of smoking related deaths around the world.
